Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market Analysis-2027Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market Report Analyses competitive environment such as key players, future trends, growths, challenges and acquisitions in the market.
Cytomegalovirus (CMV) is also known as Human Herpes Virus 5 (HHV-5). This virus is most commonly transmitted to a developing fetus. It affects males and females equally at any age. For instance, in January 2018, according to Centers for Disease Control and Prevention (CDC), around 50% adults suffer from CMV infections in U.S. Increasing approval activities for novel therapies is expected to drive the market growth. For instance, in January 2016, Fate Therapeutics Inc. received approval from the U.S. Food and Drug Administration for its new programmed cellular immunotherapy ProTmune. It is used for prevention of acute CMV infection and GvHD (Graft- versus-Host Disease) infection. Browse Research Report: https://www.coherentmarketinsights.com/ Furthermore, in July 2012, University of Alabama at Birmingham initiated clinical phase II study of quadrivalent HPV recombinant vaccine. It is used for the treatment of HPV (types 6, 11, 16, 18) infections. This study is expected to complete in November 2020. In January 2018, Shire Company received approval from the U.S. Food and Drug Administration for its new investigational treatment drug Maribavir (SHP620). This drug is used for the treatment of CMV infections. * The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology. Request a sample copy of this report: https://www.coherentmarketinsights.com/ Key Takeaways of the Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market: The global Human Papillomavirus (HPV) and Cytomegalovirus (CMV) therapeutics market is expected to witness a CAGR of 6.0% during the forecast period (2018 – 2026), owing to increasing prevalence of cervical cancer in U.S. For instance, according to WHO (World Health Organization) Major players operating in the global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market include, Allergan, Bausch Health, GlaxoSmithKline, Lee's Pharmaceutical Holdings, Merck Sharp & Dohme, Fougera Pharmaceuticals, Clinigen Group plc., Perrigo Company plc., Roche Holding AG, Biotest AG, and Fresenius Kabi Buy-Now this research report: https://www.coherentmarketinsights.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|